Sir, The importance of immunosuppression as risk and prognostic factor for periorbital non-melanoma skin cancers
We read with great interest the article by RC Gerring et al 1 regarding prognostic factors and survival rates in a retrospective case series of patients who underwent orbital exenteration for non-melanoma skin cancers (NMSC). The authors have thoroughly described the correlation between survival rates and some factors which are thought to influence the prognosis after orbital exenteration.
Their article does not make any reference to the important relation between immunosuppression and the behaviour of NMSC. There is a good deal of evidence that shows that azathioprine and cyclosporin, as well as other agents, adversely affect such cancers. 2, 3 A direct carcinogenic effect has been described in transplant patients for both azathioprine and cyclosporin, beside their primary immunosuppressive role. The former acts as mutagen and photosensitizer by increasing the level of its metabolite 6-thioguanine, while the latter seems to upregulate the transforming growth factor β (TGF-β), a cytokine implicated in cells proliferation and transformation.
Immunological cancer surveillance systems in patients using these drugs in the long term are known to be impaired in the detection and eradication of precancerous lesions. Finally, evidences suggest that also immunosuppression related to HIV/AIDS, non-Hodgkin lymphoma and chronic lymphocytic leukaemia may increase the risk of developing more aggressive SCCs. 4, 5 Even assuming that no immunosuppressed individuals were present in Gerring et al's 1 sample, we believe that considering immunosuppression among the potential prognostic factors is mandatory as far as NMSC are concerned. This is extensively outlined in many studies, including major reviews and meta-analysis.
Sir, Response to 'The importance of immunosuppression as risk and prognostic factor for periorbital non-melanoma skin cancers'
We would like to thank Dr Albanese for his interest in our recent publication, RC Gerring et al. 1 Although there is no data specifically looking at periorbital skin malignancies, there is significant evidence to support an increased risk for the development of nonmelanoma skin cancer after solid organ transplant at an approximate rate of 65-250-fold for squamous cell carcinoma and 10-fold for basal cell carcinoma as compared to the general population. 2, 3 The pathophysiology underlying these significantly increased skin cancer rates is thought to be through both the carcinogenic action of immune suppressive agents, 4, 5 as well as impaired eradication of precancerous changes related to immune suppression. 6 Among transplant patients, known risk factors for the development of skin cancer after transplantation include fairer skin type, level of immune suppression, and degree of ultraviolet exposure. 3, 7 Bone marrow transplantation has also been shown to increase the risk of nonmelanoma skin cancers in both children 8 and adults. 9 Given the increasing incidence of both solid organ and bone marrow transplantation, and increased survival after these therapies, immune suppression state in relation to skin cancer is an especially important topic of interest.
Unfortunately, we were not able to obtain this historical patient information consistently as part of our retrospective chart review (study time period of 2002-2012). We were able to obtain historical patient data with regards to skin cancer history, however, significant prior medical history data was often limited. For this reason, we were not able to include immune suppression as part of our analysis. We do, however, appreciate its importance as a potential prognostic indicator and will consider this upon any potential future research.
